Systematic Evaluation of Shenmai Injection for Prevention and Treatment of Cardiotoxicity Induced by Chemotherapy of Malignant Tumor / 中国中医药信息杂志

ABSTRACT

Objective To systematically evaluate the clinical efficacy of Shenmai Injection for the prevention and treatment of cardiotoxicity induced by chemotherapy of malignant tumor. Methods Literature about RCTs of Shenmai Injection for the prevention and treatment of cardiotoxicity induced by chemotherapy of malignant tumor in CNKI, Wanfang Database, CBM, VIP, Pub Med, Cochrane Library, Embase, and Web of Science was retrieved by computer from the establishment of database to March 2017. Two investigators independently conducted literature screening, data extraction, and literature quality evaluation. Rev Man 5.3 software was used for Meta-analysis. Results 14 articles were included in the study, involving 1105 patients. The results of Meta-analysis showed that the incidence of abnormal electrocardiogram in Shenmai Injection group was significantly lower than that in control group [RR=0.36, 95％CI (0.29, 0.44), P＜0.000 01]. CK-MB elevation value [SMD=-0.29, 95％CI (-0.58, 0.00), P=0.05]and c Tn T elevation value [SMD=-1.28, 95％CI (-2.48, -0.09), P=0.04]in Shenmai Injection group were less than control group, with statistical significance. Conclusion Shenmai Injection is beneficial to the prevention and treatment of early acute cardiac toxicity and myocardial injury induced by chemotherapy of malignant tumor. However, more large-scale, multi-center, and high-quality clinical RCTs are needed for further verification